The broker unveiled a forecast of US$5.6mln in revenues for 2016, up from US$2.1mln in 2015, with 88% growth in the flagship PIFA Heparin/PF4 rapid assay products.
Mark Brewer, analyst at broker finnCap says, the medical diagnostic maker, has the potential for stronger growth in the second half of the year “through the launch of new products”.
“The core and the key to driving growth in the short term is how well they do with the heparin-induced thrombocytopenia diagnostic” he adds.
Brewer’s note inspired a 10% rise in Aker’s shares. The stock has gained 73% since the start of 2016.